Argobio and the Institut Pasteur launch Enodia Therapeutics: A biotech company with a new approach for Targeted protein Degradation

Turning groundbreaking research from the Institut Pasteur with the support of Argobio’s start-up studio, into novel treatments for cancer, inflammatory diseases and viral infections. The platform leverages state-of-the-art generative artificial intelligence (AI) to design selective inhibitors of the Sec61/translocon molecular complex for blocking and degrading disease-causing proteins. Enodia Therapeutics is the winner of Pfizer sponsor BioLabs Paris Hotel Dieu coveted 2025 Golden Ticket competition.

Find out more